Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers were specifically looking at those with a history of substance use.
Researchers followed a small group of people with highly drug-resistant virus taking Trogarzo plus an optimized background regimen.
The viral suppression rate in this group was considerably higher than that seen in the same clinics a decade before.
Receiving viral load results within hours as opposed to weeks was linked to higher rates of HIV suppression and retention in medical care.
Researchers analyzed changes in weight and signs of inflammation among people starting HIV treatment.
In particular, having a high hep B viral load increases the risk of women with HIV transmitting the latter virus to their newborns.
People with commercial insurance stayed on PrEP about twice as long as those covered by Medicaid.
Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
People with HIV have high rates of chronic pain as well as opioid usage.
The disease tends to strike HIV-positive individuals at younger ages and with less smoking experience than the general population.
“The Düsseldorf Patient” has been off HIV meds only since November 2018, so it is much too early to determine whether he has been cured.
Women in a global study began an HIV treatment regimen based on one of the two drugs after 20 weeks of gestation.
Tivicay was associated with a higher rate of viral suppression at delivery compared with Sustiva.
Chronic obstructive pulmonary disease is an umbrella term for various progressive lung diseases, including emphysema.
The diagnosis rate fell by 50 percent in just two years among gay and bi men who attended sexual clinics at least twice in one year.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.